🇺🇸 FDA
Patent

US 9096625

BCL-2/BCL-XL inhibitors and therapeutic methods using the same

granted A61KA61K31/496A61K31/675

Quick answer

US patent 9096625 (BCL-2/BCL-XL inhibitors and therapeutic methods using the same) held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN expires Mon Jul 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Grant date
Tue Aug 04 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/496, A61K31/675, A61K33/30, A61K45/06